NCT00996762View on ClinicalTrials.gov

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

PHASE1CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

November 12, 2009

Primary Completion Date

September 18, 2012

Study Completion Date

September 18, 2012

Conditions
Neoplasms, Breast
Interventions
DRUG

lapatinib

1250 mg or 1500 mg lapatinib commercial tablet

Trial Locations (9)

20007

GSK Investigational Site, Washington D.C.

30341

GSK Investigational Site, Atlanta

33905

GSK Investigational Site, Fort Myers

37203

GSK Investigational Site, Nashville

38120

GSK Investigational Site, Memphis

48202

GSK Investigational Site, Detroit

85259

GSK Investigational Site, Scottsdale

85724

GSK Investigational Site, Tucson

120-752

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00996762 - A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib | Biotech Hunter | Biotech Hunter